Literature DB >> 17341897

Phyllodes tumors of the breast diagnostic and therapeutic dilemmas.

Josip Fajdić1, Nikola Gotovac, Zlatko Hrgović, Jozo Kristek, Vlado Horvat, Manfred Kaufmann.   

Abstract

BACKGROUND: This article compares experiences in the diagnosis and treatment of phyllodes tumors from 2 regional institutions with the relevant literature. PATIENTS AND METHODS: From 1991 to 2005, 2,848 breast cancer patients were treated in our institutions, 36 (1.44%) for phyllodes tumors. The average tumor size was 5.1 cm (range 1.4-19.6). Triple assessment was the standard diagnostic algorithm. Wide excision with tumor-free margins was carried out in 29 (80.5%) cases and mastectomy in 7 (19.4%) cases. Axillary lymphadenectomy was performed in patients with positive lymph nodes.
RESULTS: Histology showed the phyllodes tumors to be benign in 27 (75.0%), malignant in 6 (16.6%), and borderline in 3 (8.3%) cases. Follow-up was from 5 months to 16 years. In this period, recurrences of 3 (8.3%) malignant and 2 (5.6%) benign phyllodes tumors were diagnosed and treated. 10 (27.7%) patients treated with wide local excision showed deformities in the form of scarring. The steroid receptor status was of no prognostic value in our patients, and chemotherapy was used in only 1 (2.7%) patient. 5-year survival was 86.2%.
CONCLUSION: Our study shows that tumor size, margin infiltration, mitotic activity and degree of cellular atypia are important prognostic factors. Problems in diagnosing this condition arise from its similarity to fibroadenoma. Although wide local excision is usually the treatment of choice, tumor recurrence is common. Axillary lymphadenectomy in malignant phyllodes tumors is, in our opinion, still controversial.

Entities:  

Mesh:

Year:  2007        PMID: 17341897     DOI: 10.1159/000099580

Source DB:  PubMed          Journal:  Onkologie        ISSN: 0378-584X


  7 in total

Review 1.  Phyllodes tumors of the breast: diagnosis, treatment and prognostic factors related to recurrence.

Authors:  Zhi-Rui Zhou; Chen-Chen Wang; Zhao-Zhi Yang; Xiao-Li Yu; Xiao-Mao Guo
Journal:  J Thorac Dis       Date:  2016-11       Impact factor: 2.895

2.  Giant Metastatic Breast Phyllodes Tumour with an Elusive Diagnosis: A Case Report and Literature Review.

Authors:  Raquel Basto; Tatiana Cunha Pereira; Luís Rei; Fábio Rêgo Salgueiro; Joana Magalhães; Maria João Sousa; Ana Raquel Monteiro; Filipa Macedo; Rita Félix Soares; Teresa Carvalho; Paula Jacinto; Gabriela Sousa
Journal:  Eur J Case Rep Intern Med       Date:  2021-08-23

Review 3.  Phyllodes tumours of the breast: a consensus review.

Authors:  Benjamin Y Tan; Geza Acs; Sophia K Apple; Sunil Badve; Ira J Bleiweiss; Edi Brogi; José P Calvo; David J Dabbs; Ian O Ellis; Vincenzo Eusebi; Gelareh Farshid; Stephen B Fox; Shu Ichihara; Sunil R Lakhani; Emad A Rakha; Jorge S Reis-Filho; Andrea L Richardson; Aysegul Sahin; Fernando C Schmitt; Stuart J Schnitt; Kalliopi P Siziopikou; Fernando A Soares; Gary M Tse; Anne Vincent-Salomon; Puay Hoon Tan
Journal:  Histopathology       Date:  2016-01       Impact factor: 5.087

4.  Immediate breast reconstruction with a saline implant and AlloDerm, following removal of a Phyllodes tumor.

Authors:  Shirley A Crenshaw; Michael D Roller; Jeffery K Chapman
Journal:  World J Surg Oncol       Date:  2011-03-21       Impact factor: 2.754

5.  Aggressive malignant phyllodes tumor.

Authors:  Nathan Roberts; Dianne M Runk
Journal:  Int J Surg Case Rep       Date:  2015-01-15

6.  Local recurrence for phyllodes tumours of the breast: Systematic review and meta-analysis.

Authors:  Ioannis Boutas; Adamandia Kontogeorgi; Dionysios Dimas; Nektarios Koufopoulos; Sofia-Maria Genitsaridi; Kyparissia Sitara; Sophia Kalantaridou; Constantine Dimitrakakis
Journal:  Oncol Lett       Date:  2022-08-22       Impact factor: 3.111

7.  Prognostic factors in breast phyllodes tumors: a nomogram based on a retrospective cohort study of 404 patients.

Authors:  Zhi-Rui Zhou; Chen-Chen Wang; Xiang-Jie Sun; Zhao-Zhi Yang; Xing-Xing Chen; Zhi-Ming Shao; Xiao-Li Yu; Xiao-Mao Guo
Journal:  Cancer Med       Date:  2018-02-26       Impact factor: 4.452

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.